Advanced searches left 3/3

Brain Tumor - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 June 2022

* If you want to update the article please login/register

Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors

"The main aim of this research is to determine the correlation between quantitative MRI imaging with histopathological characteristics and genetic markers in pre-therapy setting and treatment response and clinical outcomes in post-treatment settings. " ENGROUP 2: All patients with brain tumors that show at post-therapy follow-up to imaging progression receive serial imaging as part of medical therapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT02956291


Cognitive Behavioral Therapy for Insomnia in Primary Brain Tumor Patients

"The current research findings supports the hypothesis, acceptability, and preliminary efficacy of the Cognitive Behavioral Therapy for Primary Brain Tumor Patients in Insomnia. " Participants will be required to do the following tasks in this report: Participants will be required to attend six times for group CBT-I sessions via Zoom lasting 90 minutes each, and will be asked to do the following items: Meet with a qualified interventionist six times for group CBT-I sessions that last 90 minutes each. As part of the operation, participants will be asked to only use first names and will have complete weekly sleep diaries. The patient's experience with the CBT-I program will be questioned at the follow-up time point. Patients who are regular blood draws as part of Massey Cancer Center's treatment will have an IL-6 added to their normal blood draw. THose who are not receiving regular blood draws as part of their standard of care, or those who are not patients at Massey Cancer Center will forego this portion of the procedure. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT04919993


Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study

"To determine the success of a home-based, computerized, cognitive training service for patients with pediatric brain tumors treated in various Children Oncology Group hospitals" will be determined. In order to design a large clinical trial, we need to determine the effect size of this program on measures of attention and working memory in patients with brain tumors treated with CRT. Each patient has an interventional coach who has online access to patient's educational sessions and findings. As in arm I, each patient also has an interventional coach. After completion of the study and six months after completion of study, patients in both arms complete a brief neuropsychological/behavioral evaluation involving the Wechsler Intelligence Scale for Children, the Children's Memory Scale, and the California Verbal Learning Test-Children's Version. Participants are followed up within 3 weeks and then six months after completion of study, and then at six months. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT01503086


Assessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients: an Observational Study

"Background: Sleep disorders are among the most common and severe signs observed in the Primary Brain Tumor cohort, and prevalence rates are tied to oncologic therapies, particularly radiotherapy. " Smart wearable devices have the ability to provide detailed information about human sleep and circadian rhythms with lower risks of data loss, as long as they sync automatically and require less charging time. The Fitbit Charge 3TM version does better than actigraphy and is the most similar to polysomnography, the gold standard of sleep detection, according to previous smart wearable experiments in healthy controls. Objectives: To investigate sleep disturbances in PBT patients using the physiological sleep monitoring techniques from smart wearable devices, as well as the correlation with self-reported sleep studies. Eligibility: PBT patients must be registered in the Neuro-Oncology Branch's Natural History Study study. Exclusion: Participants who are unable or unable to synchronize or link their Fitbit smart wearable device to their personal smart phone will be excluded. According to the study, a total of 160 PBT participants will enroll. The investigation will also include the collection of nationally reported patient outcomes for sleep and circadian rhythms. Participants will be sent sleep diaries to be completed at home for the fourth week of recording and will be asked to complete the PRO measures during the fourth week after the study's completion.

Source link: https://clinicaltrials.gov/ct2/show/NCT04669574


Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

"Outcomes for children with persistent or progressive cerebellar malignant brain tumors are extremely poor, and there are a lack of effective salvage techniques after a patient complies with standard treatments are often inadequate. " The tumor cell destruction of G207 in the tumor not only kills the cancer cells, but also causes the tumor cell to function as a factory that produces new virus. These virus particles are released as the tumor cell dies and can then spread to other tumor cells in the immediate area, and continue the process of tumor formation. In addition to this direct oncolytic action, the virus results in an anti-tumor immune reaction; the virus is immunogenic and produces a debris field that exposes cancer cell antigens to immune cells, which can also affect other cancer cells. The viral oncolytic effect of the virus and the virus's immune response give a "one-two punch" at attacking cancer cells. In preclinical studies, a single 5 Gy dose of radiation within 24 hours of virus inoculation to the tumor increased virus propagation and tumor cell killing. Children's of Alabama found that the safety of G207 has been demonstrated in three phase I clinical trials involving adults with supratentorial high-grade gliomas adults at the University of Alabama and in an ongoing phase I clinical trial involving children with recurrent supratentorial brain tumors. G207 will be administered alone by the first cohort, and the following cohorts will be given G207 at one of three doses, followed by a 5 Gy dose of radiation to active areas of tumors.

Source link: https://clinicaltrials.gov/ct2/show/NCT03911388


A Phase 1 Study of Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

"Stratum A" refers to children with recurrent or progressive malignant brain tumors, while Stratum B consists of adults with recurrent or progressive malignant brain tumors. Children are malignant brain tumors that have recurrent or progressive cerebral tumors. PRIMARY OBJECTIVES: Children To determine the efficacy and tolerability of magrolimab in children with recurrent or progressive brain tumors. In adults with recurrent or progressive malignant brain tumors, the recommended Phase 2 dose for magrolimab is determined. In children and adults with recurrent or progressive malignant brain tumors, investigate the changes in the immune cells in the peripheral blood and CSF, as well as changes in the immune cytokine environment in the peripheral blood serum and CSF during treatment with magrolimab. Participants may continue to receive magrolimab for up to 12 months or longer after the time of study completion, pending discussion with research chairs, and government sponsoring. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT05169944


A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors

"Therefore, we will conduct a controlled trial to determine the effects of PA on children treated with CRT for brain tumors' cognitive function. " The immediate intervention group will participate in the enhanced PA intervention service for the first 12 weeks followed by 12 weeks of PA maintenance on their own, while the delayed intervention group will continue to practice as normal for the first 12 weeks and the enhanced PA intervention scheme for the second 12 weeks. OBJECTIVES: - To determine the effects of a 12-week enhanced physical fitness home intervention for brain tumor patients treated with CRT for brain tumors in children treated with CRT for brain tumors, compared to a control group who was exercising regular physical activity during the first 12 weeks. Group 1 : The immediate intervention group will be randomized to one of two groups for the first 12 weeks, followed by 12 weeks of PA maintenance on their own. The delayed intervention control group will return to their normal physical fitness for a year, followed by increased PA home involvement for a year. Group 2 : "The intervention group will continue to perform their PA levels on their own for the next 12 weeks after the completion of the first 12 weeks at home and the follow-up studies, and the intervention group will remain on the ground for 12 weeks. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT02153957


Safety and Imaging of Post-Operative Low Dose Versus Standard Dose Dexamethasone in Patients With Primary or Metastatic Brain Tumors: a Randomized, Double-blinded Feasibility Study.

"PRIMARY OBJECTIVES: I. Determine the possibility of giving lower doses of dexamethasone post-operatively in patients with mild to moderate cerebral edema pre-operatively. In participants on Arm 1 and Arm 2, quantitatively assess changes in the number of cerebral edema post-operatively in participants. Describe changes in the amount of cerebral edema in Arm 1 and Arm 2 participants' separately. On days 1-3 post surgery and tapered dexamethasone IV q 12 h on days 1-3, patients receive standard dose dexamethasone IV q 12 h and tapered dexamethasone PO q 12 h in the absence of disease progression or unacceptable toxicity in the absence of disease progression or unacceptable toxicity. Patients are given a lower dose of dexamethasone PO q 12 h for three days. Patients on days 1-3 post surgery and tapered dexamethasone IV q 12 h on days 1-3, with no signs of disease progression or unacceptable toxicity in the absence of disease progression or unacceptable toxicity. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT05139043


NCI-Sponsored Multi-Disciplinary Study for MR Imaging of Intravenous Superparamagnetic Crystalline Particle Ferumoxytol in Primary High-Grade Brain Tumors and/or Cerebral Metastases

"Investigate the benefits of a ferumoxytol and gadolinium-based contrast agent for enhanced imaging biomarkers of malignant brain tumors in a single imaging session by comparing dynamic susceptibility contrast determined relative cerebral blood volume and dynamic contrast enhancement determined vascular permeability. " V. Examine differences in patients with prior therapy versus no prior therapy. OUTLINE: Patients receive ferumoxytol non-stoichiometric magnetite intravenously beginning approximately 15 seconds after beginning 3T DSC-MRI and GBCA IV, approximately 1 minute and 50 seconds after starting of 3T DCE-MRI on day 1. Patients also undergo MRI without contrast at baseline and on day 2," says the author.

Source link: https://clinicaltrials.gov/ct2/show/NCT00103038

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions